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Abstract 
A simplified bicyclic scaffold inspired by the antifungal natural product sordarin was designed and 
synthesized which maintains the carboxylic acid/aldehyde (or nitrile) pharmacophore. Docking studies 
with the target for sordarin, the fungal protein eukaryotic elongation factor 2 (eEF2), suggested that the 
novel scaffolds may bind productively. A densely functionalized chiral cyclopentadiene was constructed 
in 8 steps and utilized in a Diels-Alder reaction with acrylonitrile. The resulting [2.2.1] cycloheptene was 
transformed into a scaffold possessing vicinal carboxylic acid and nitrile groups, with orientations 
predicted to provide high affinity for eEF2. The synthetic approach disclosed here sets the stage for a 
renewed medicinal chemistry campaign against eEF2. 
Graphical abstract 
A simplified bicyclic scaffold inspired by the natural product sordarin was designed and synthesized 
which will facilitate the preparation of novel antifungal agents. 
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An estimated 1.5 million people die each year from invasive fungal infections (IFIs) [1]. Clinical 
options for the treatment of IFIs are extremely limited and generally only include a small number 
of azole, echinocandin, and polyene (amphotericin B) antifungals. Of these treatments, only the azoles 
are orally available, but their value has been diminished by the increasing prevalence of resistant 
strains [2]. For these reasons, novel classes of antifungal drugs are urgently needed [3]. In the 1990s it was 
discovered that derivatives of the natural product sordarin (1), known since the 1960s as an 
antibacterial and antifungal agent [4], are highly active against pathogenic fungal species, particularly C. 
albicans (Fig. 1, e.g. 3 to 5) [5], [6], [7]. A mode of action was deduced for sordarin that is unique for 
antifungals, and appears to be related to that of the antibacterial fusidic acid[8], [9]. Sordarin halts protein 
synthesis at fungal ribosomes by binding to eukaryotic Elongation Factor 2 (eEF2) and inhibiting the 
interaction of eEF2 with ribosomal stalk proteins [10], [11], [12]. Importantly, sordarin derivatives are able to 
selectively eradicate numerous fungal strains, including fluconazole-resistant C. albicans, without 
significant toxicity to mammalian cells [13], are orally available, and have shown promising results in 
animal models of invasive fungal infections [7], [14], [15], [16]. 
 
Figure 1. SAR of semisynthetic sordarin analogs and designed simplified bicyclic scaffold. 
Despite significant efforts by the pharmaceutical industry in the 1990s and early 2000s to 
develop semisynthetic sordarin analogs via ready modification of the glycosyl portion of the molecule, 
no eEF2 inhibitors have advanced to clinical stages. The unmet potential of this class of molecules is 
amplified by findings that some derivatives also show broad spectrum activity, including against 
pathogenic Aspergillus species (5, Fig. 1) [7]. However, this potential is attenuated by the synthetic 
challenge of modifying the complex sordarin core, which is prone to in vivo oxidation of 
the cyclopentane ring to generate poorly active metabolites [17], [18]. Impressive total syntheses of 
sordarin or its aglyconesordaricin have been reported by Kato [19], Mander [20], and Narasaka [21], but the 
reported routes are lengthy and not amenable to convenient modifications of the sordarin core. 
Our interest in function-oriented synthesis [22] as a strategy for simplifying and modifying natural 
products [23] led us to re-examine the complex diterpene core of sordarin, with the goal of generating 
novel scaffolds that could be more easily modified to improve properties such as metabolic stability and 
activity against resistant strains. An unsuccessful attempt at identifying a simplified sordarin scaffold 
with potent antifungal activity was reported by Cuevas in 1998, involving a monocyclic cyclopentane[17], 
but otherwise we are not aware of the de novo synthesis of sordarin-inspired scaffolds for antifungal 
applications. Novel scaffolds and synthetic approaches to this class of inhibitors could reignite the 
dormant interest in eEF2 as a target for potent and safe antifungal agents. 
More recently, our interest in novel scaffolds is supported by the x-ray crystal structures of 
sordarin or related compounds with eEF2 that were reported subsequent to the majority of 
semisynthetic medicinal chemistry efforts [9], [24], [25]; these could enable the prioritization of novel 
compound designs with routine docking algorithms. Published patents and structure-activity 
relationship (SAR) studies, and inspection of the sordarin–eEF2 x-ray structure reported by Andersen [24], 
highlight the necessity of a carboxylic acid at C1 and an aldehydeor nitrile [5] at C2 of the bicyclic core of 
sordarin (Fig. 2). A carboxylic acid at the bridgehead position of the scaffold forms hydrogen bonds with 
a backbone amide (Glu524) of eEF2, as well as two bridging water molecules (Fig. 2, left). The acid 
moiety is essential for activity, and no alternative functional groups have been reported to be effective. 
The aldehyde of sordarin acts as a hydrogen bond acceptor for the backbone amide of Ala562; a nitrile 
was reported to be an effective replacement of this aldehyde moiety, and in some cases was more 
potent [5]. Interestingly, the glycosyl moiety is not critical for activity against specific strains, and highly 
potent analogs have been reported possessing aliphatic alkyl chains [5]. 
 
Figure 2. X-ray structure of sordarin with eEF2 (left); docked structure of designed analog 2a (right). 
With this and other SAR data in mind, we designed novel scaffolds that maintain 
the pharmacophore of sordarin, but with removal of the fused cyclopentane ring, and replacement with 
alternative metabolically stable groups (2, Fig. 1). We hypothesized that scaffolds with decreased 
complexity such as 2could also facilitate SAR studies and the subsequent improvement of 
physico/physiochemical properties that are not feasible with the natural scaffold. A docking study was 
performed with compounds of type 2 and the sordarin–eEF2 x-ray structure (PDB 1N0U[24]) using 
FITTED® by Molecular Forecaster [26]. Our simplified sordarin analogs generally yielded similar docking 
poses to sordarin and comparable docking scores to compounds with simple alkyl glycosyl replacements 
such as 3that have been reported to be potent antifungal agents against S. cerevisiae[5]. A representative 
docking pose is given in Fig. 2(right), in comparison to the x-ray structure in Fig. 2 (left) of sordarin with 
eEF2, which suggests that nitriles such as 2a will indeed be able to effectively replace 
the aldehyde moiety of sordarin as an H-bond acceptor for the backbone amide of Ala 562. 
A retrosynthesis of compounds of type 2 is depicted in Fig. 3. The Diels-Alder cycloaddition could 
permit the late stage introduction of a variety of substituents at C-2. We prioritized nitrile-containing 
compounds over aldehydes for their better stability and tolerance of a range of reaction conditions. For 
ease of synthesis, we also prioritized analogs alkylated at C-5 instead of C-6, especially since the x-ray 
structure of eEF2 suggests that various substituents could be tolerated in both 
positions. Cyclopentadienes of type 6 were selected as key synthetic targets, with the silylether 
substituent able to polarize the diene to provide the desired regioselectivity with the nitrile and latent 
carboxylic acid moieties on adjacent carbons, as well as increasing its reactivity. A related intermolecular 
Diels-Alder reaction was reported by Ciufolini [27]. One important disadvantage to substituted 
cyclopentadienes is that they are prone to 1,5-hydride or alkyl shifts [28], but we were inspired by the 
work of Gleason and coworkers disclosing that the silylether could greatly increase the stability of 
cyclopentadienes to undesired hydride shifts (isomerization) [29]. Cyclopentadienes of type 6 could be 
generated by enolization of an enone; enones of type 7 could be prepared via 
a carbonylation of triflate 8, followed by an allylic oxidation reaction. Aldol 
reaction between cyclopentanone and formaldehyde, with a subsequent generation of 
the kinetic enolate and trapping with an appropriate electrophile, would generate enol triflate 8. 
 
Figure 3. Retrosynthesis of simplified sordarin analogs. 
The synthesis of the desired cyclopentadienes proceeded broadly according to plan, with 
racemic materials generated in our first-generation synthesis disclosed here (Scheme 1). An excess 
of cyclopentanone was reacted with formaldehyde in an aldol reaction [30], followed by distillation and 
protection of the alcohol with TBDPSCl to generate large quantities of silylether 9, after recrystallization. 
After screening several bases and electrophiles, the kinetic enol triflate 10 was obtained in quantitative 
yield using NaHMDS and PhNTf2 at –40 °C. Palladium-catalyzed carbonylation and trapping 
with methanolproceeded smoothly to yield enoate 11. Allylic oxidation using Corey’s reported protocol 
(t-BuOOH, cat. Pd(OH)2/C) yielded enone 12[31]. Reduction of both the ketone and ester moieties with 
DIBAL-H generated a diol intermediate as an inconsequential mixture of diastereomers, which was 
acetylated selectively at the primary alcohol to give 13, then the secondary alcohol was oxidized with 
PCC to yield the enone 14. 
 
Scheme 1. Synthesis of cyclopentenone 14. 
Enone 14 was treated with TBSOTf and base to generate cyclopentadiene 15, which was 
subjected to a variety of Diels-Alder reactions with different aldehyde, ester, and nitrile-containing 
dienophiles (Scheme 2). The most useful product was obtained from reaction with excess acrylonitrile; 
even though a 1:1 mixture of endo/exo diastereomers was obtained, these were separable 
by chromatography at a later stage. Diels-Alder reactions with carboxyl-substituted cyclopentadienes 
(instead of hydroxymethyl-substituted systems such as 15), were unsuccessful, likely due to poor 
matching of HOMO/LUMO levels. 
 
Scheme 2. Synthesis of first-generation antifungal scaffold: bicyclic nitrile acid 23. 
The racemic mixture of cycloadducts 16 underwent selective removal of the silylenol ether using 
BF3 etherate [32]. The remaining acetate protecting group proved to be problematic for several 
transformations, so it was removed under basic conditions, and 
the endo/exo diastereomeric alcohols were separated by flash chromatography; the isolated yield is not 
reflective of mixed fractions that were omitted. The desired endoproduct 17a and exo 
diastereomer 17b were isolated and assigned via COSY and NOESY NMR, inspection of the 1H 
NMR coupling constants, and comparison to literature coupling constants. Protons b and c (Scheme 2, 
bottom) of the exo isomer 17b were differentiated by the negligible coupling of Hb with the bridgehead 
Hd, due to a dihedral angle approaching 90° [33]. 3Jab(9.2 Hz) is consistent with the cis coupling reported 
by Williamson for a nitrile-substituted bicyclo[2.2.1]heptene (9.3 Hz) [34], therefore our data are 
consistent with Ha of 17b residing on the endo face of the bicycle (see Supporting Information for 
spectra). 
Initial efforts at protection of 17 with PMB or Bn were unsuccessful, so a THP protecting 
group was utilized to cleanly give 18. Several functional group transformations of the C-5 ketone are 
presently being explored, but to maintain lipophilicity on the eastern face of the bicycle we elected to 
methenylate the ketone with a Wittig reaction. Elevated temperatures were required (90 °C), but 
the alkene 19 was cleanly obtained without epimerization of the α-nitrile carbon. Removal of the TBDPS 
protecting group with TBAF and alkylation of the resulting alcohol with n-pentyl iodide generated 
the ether 21, containing a simple alkyl chain analogous to those on sordarin analogs reported to be 
highly potent against S. cerevisiae[5]. Analogs with extended alkyl chains are not expected to be 
metabolically stable (due to their likely accessibility to the active site of cytochromes P450), but for ease 
of synthesis we elected to build such an analog first to validate the scaffold synthesis prior to attaching 
more complex glycosyl groups presumably required for high potency against species such as C. albicans. 
The THP group of 21 was removed under acidic conditions, then subjected to a Jones oxidation to 
generate the desired carboxylic acid 23, which represents our first simplified sordarin analog. 
Though it was inactive against several strains of C. albicans at concentrations up to 8 μg/mL 
using the CLSI M27-A3 broth microdilution method (RPMI + MOPS, pH 7.0 as the liquid medium), the 
preparation of 23 validates our intermolecular Diels-Alder strategy towards the preparation of 
functionalized bicyclic scaffolds with the requisite positioning of carboxylic acid and aldehyde/nitrile 
moieties for inhibition of fungal eEF2. Our present efforts are directed towards the addition of alkyl and 
aryl substituents at C-2, the incorporation of validated glycosylgroups, and the development of 
an asymmetric synthesis of the desired bicyclic scaffolds. Our novel synthetic strategy facilitates the 
exploration of unaddressed structure-activity relationships of sordarin-type eEF2 inhibitors, and may 
lead to the identification of antifungal agents with improved properties. 
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